For LINC00511, it can combine with EZH2 and LSD1 in vivo, downregulate the expression of LATS2 and KLF2, and promote the progression of NSCLC (Zhu F. Y. et al., 2019). Here, KLF2 is linked to non-small cell lung carcinoma.